Nautilus Biotechnology, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Nautilus Biotechnology, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | ($59.00M) | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | ($70.78M) | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | ($63.68M) | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | ($57.92M) | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | ($50.32M) | Feb 23, 2023 |
| FY2020 | Dec 31, 2020 | ($523.1K) | Mar 30, 2021 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2020 | Dec 31, 2020 | ($576.0K) | Mar 30, 2021 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $191.11M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $242.74M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $305.57M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $350.05M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $398.45M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $85.01M | Feb 24, 2022 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $34.14M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $34.01M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $40.21M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $35.13M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $34.87M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $6.31M | Feb 24, 2022 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $156.97M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $208.73M | Feb 26, 2026 |
| FY2025 | Dec 31, 2023 | $265.35M | Feb 26, 2026 |
| FY2024 | Dec 31, 2022 | $314.92M | Feb 27, 2025 |
| FY2023 | Dec 31, 2021 | $363.58M | Feb 28, 2024 |
| FY2022 | Dec 31, 2020 | ($29.72M) | Feb 23, 2023 |
| FY2020 | Mar 26, 2020 | $0 | Mar 30, 2021 |
| FY2021 | Dec 31, 2019 | ($14.51M) | Feb 24, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 0 | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | 0 | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | 0 | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | 0 | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | 0 | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | 0 | Feb 24, 2022 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $12.39M | Feb 26, 2026 |
| FY2025 | Dec 31, 2024 | $27.65M | Feb 26, 2026 |
| FY2024 | Dec 31, 2023 | $19.40M | Feb 27, 2025 |
| FY2023 | Dec 31, 2022 | $114.52M | Feb 28, 2024 |
| FY2022 | Dec 31, 2021 | $185.62M | Feb 23, 2023 |
| FY2021 | Dec 31, 2020 | $36.61M | Feb 24, 2022 |